论文部分内容阅读
目的 观察普拉洛芬 (Pranoprofen)滴眼液控制白内障摘出和后房型人工晶状体植入术后及非感染性眼前段炎症的疗效和安全性。方法 采用临床多中心随机对照试验。试验组和对照组分别滴用 0 1%普拉洛芬滴眼液和0 0 3 %欧可芬滴眼液 ,每日 4次 ,观察 2周。结果 试验组和对照组治疗有效率相比 ,白内障术后分别为 93 6%和90 0 % ,眼前段炎症分别为 83 3 %和 88 9%。试验组不良反应发生率明显低于对照组。结论 普拉洛芬滴眼液是控制白内障术后和非感染性眼前段炎症的有效和安全的药物
Objective To observe the efficacy and safety of Pranoprofen eye drops in controlling cataract extraction and posterior chamber intraocular lens implantation and noninfectious anterior segment inflammation. Methods The clinical multicenter randomized controlled trial. The experimental group and the control group were treated with 0 1% pranoprofen eye drops and 0 0 3% ophthalmic eye drops 4 times daily for 2 weeks. Results Compared with the control group, the effective rate of the treatment group was 93.6% and 90.0% after cataract surgery, and the anterior segment inflammation was 83.3% and 88.9% respectively. The incidence of adverse reactions in the experimental group was significantly lower than that in the control group. Conclusions Pranoprofen ophthalmic solution is a potent and safe drug that controls post-cataract surgery and noninfectious anterior segment inflammation